Related Experiment Video
Updated: Oct 1, 2026
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
Published on: March 18, 2015
Analysis of the effects of daunorubicin and WP631 on transcription
J Portugal1, B Martín, A Vaquero
1Departamento de Biología Molecular y Celular, Instituto de Biología Molecular de Barcelona, CSIC, Jordi Girona, 18-26, Barcelona, 08034, Spain. jpmbmc@cid.csic.es
Abstract:
The proficiency with which anthracyclines and other DNA-binding drugs target certain sequences in eukaryotic promoters offers a potential approach to interfere with the mechanisms that regulate gene expression in tumor cells. An in vitro transcription assay has been used to compare the ability of the bisintercalating anthracycline WP631 and the monointercalating anthracycline daunorubicin in terms of their ability to inhibit initiation of transcription of the adenovirus major late promoter linked to a G-less transcribed DNA template. Both drugs inhibit basal transcription by RNA polymerase II. However, WP631 is approximately 15 times more efficient at inhibiting transcription initiation from an adenovirus promoter containing an upstream Sp1-protein binding site. The differences in the ability of each drug to inhibit transcription initiation appear to be related to the competition between Sp1 and the anthracyclines for binding to the same site. To see whether WP631's strong effect on transcription can also be observed in cells, we compared the effects of WP631 and other anthracyclines on the transcription of the c-myc gene, which promoter contains Sp1 binding sites. The resulting data suggest that WP631 might circumvent some kinds of tumor resistance at rather low drug concentrations, inhibit c-myc expression in some cell lines, and exert its antitumoral effect by inducing apoptosis.
Insights
The bisintercalating anthracycline WP631 effectively inhibits gene transcription by competing with Sp1 proteins, potentially overcoming tumor resistance. This DNA-binding drug shows promise in cancer therapy by inducing apoptosis.
Area of Science:
- Molecular Biology
- Pharmacology
- Cancer Research
Background:
- Anthracyclines are DNA-binding drugs with potential for cancer therapy.
- Targeting gene expression in tumor cells is a key strategy in cancer treatment.
Purpose of the Study:
- To compare the transcription inhibition capabilities of bisintercalating (WP631) and monointercalating (daunorubicin) anthracyclines.
- To investigate the effect of WP631 on gene expression in cancer cells, specifically targeting the c-myc gene.
Main Methods:
- In vitro transcription assays using adenovirus major late promoter with a G-less template.
- Comparison of RNA polymerase II basal transcription inhibition by WP631 and daunorubicin.
- Cell-based assays to assess the impact of WP631 on c-myc gene transcription.
Main Results:
- Both WP631 and daunorubicin inhibited basal transcription.
- WP631 was 15 times more potent than daunorubicin in inhibiting transcription from a promoter with an Sp1 binding site.
- WP631 demonstrated the ability to inhibit c-myc expression in certain cell lines.
Conclusions:
- Differences in transcription inhibition are linked to competition between anthracyclines and Sp1 for DNA binding sites.
- WP631 may overcome certain tumor resistance mechanisms at low concentrations.
- WP631's antitumoral effects may be mediated by apoptosis induction and c-myc gene inhibition.
